4.5 Article

Toxicity and structure-activity relationship (SAR) of alpha,beta-dehydroamino acids against human cancer cell lines

Journal

TOXICOLOGY IN VITRO
Volume 47, Issue -, Pages 26-37

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.tiv.2017.10.027

Keywords

Dehydroamino acids; Toxicological profile; Apoptosis; Caspases; Therapeutic agents; Structure-activity relationship (SAR)

Categories

Funding

  1. FCT/MEC [UID/QUI/50006/2013]
  2. European Union (FEDER)
  3. Norte Portugal Regional Operational Programme (NORTE), under the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000024]

Ask authors/readers for more resources

A library of N-protected dehydroamino acids, namely dehydroalanine, dehydroaminobutyric acid and dehydrophenylalanine derivatives, was screened in three human cancer cell lines [(lung (A549), gastric (AGS) and neuroblastoma (SH-SY5Y)] in order to characterize their toxicological profile and identify new molecules with potential anticancer activity. Results showed N-protected dehydrophenylalanine and dehydroaminobutyric acid derivatives have no or low toxicity for all tested cell lines. The N-protected dehydroalanines exhibit significant toxic effects and the AGS and SH-SY5Y cells were significantly more vulnerable than A549 cells. Four alpha,beta-dehydroalanine derivatives, with IC50 < 62.5 mu M, were selected to investigate the pathways by which these compounds promote cell death. All compounds, at their IC50 concentrations, were able to induce apoptosis in both AGS and SH-SY5Y cell lines. In both cell lines, loss of mitochondria] membrane potential (Delta psi m) was found and caspase activity was increased, namely endoplasmic reticulum-resident caspase-4 in AGS cells and caspase-3/7 in SH-SY5Y cells. When evaluated in a non-cancer cell line, the molecules displayed no to low toxicity, thus suggesting some degree of selectivity for cancer cells. The results indicate that a,p-dehydroalanine derivatives can be considered a future resource of compounds able to work as anticancer drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available